Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Medistem Panama has developed proprietary methods to isolate and expand highly potent mesenchymal stem cells ("Golden Cells™") from various sources. These are used in IRB-approved clinical trials targeting autoimmune and degenerative diseases such as multiple sclerosis, rheumatoid arthritis, osteoarthritis—with future plans for spinal cord injury, autism spectrum disorder and cerebral palsy. The company’s research has led to dozens of scientific publications and numerous pending patents. Clinical results have shown promising outcomes in treated patients with chronic conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Medistem Panama.